15th Jun 2006 07:46
Deltex Medical Group PLC15 June 2006 Deltex Medical Group plc Launch of CardioQ upgrade to broaden critical care applications 15 June 2006: Deltex Medical Group plc ('Deltex Medical' or the 'Company'), theAIM listed haemodynamic monitoring company, today announces that it is launchingan additional parameter for its CardioQ(TM) monitor on 19 June 2006. DO2 is a measure of oxygen delivery which can be measured following laboratoryassessment of haemogloblin levels and with reference to cardiac outputmeasurements. DO2 is used by doctors who follow a specific fluid managementprotocol for the post-operative care of high-risk surgical patients in intensivecare units. The DO2 parameter and its presentation on the CardioQ is being launchedfollowing successful evaluations in the intensive care units of selected majorUK teaching hospitals. Andy Hill, Deltex Medical's Chief Executive, commented: "We have added DO2 to the CardioQ to develop further its position as the cardiacoutput monitor of choice in intensive care units in the UK. The parameter hasrecently been included in a small number of tender specifications; being able tooffer DO2 means that we can meet the specification and therefore compete on thebasis of the CardioQ's competitive advantages of price, ease of use and safetyas well as it being the only haemodynamic monitoring technology which actuallymeasures blood flow beat to beat in real time." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman [email protected] Hill, Chief Executive [email protected] Phillips, Finance Director [email protected] Financial Dynamics 0207 831 3113David Yates [email protected] Gilbert [email protected] Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical